Insulet (NASDAQ:PODD) Shares Gap Down – Should You Sell?

Insulet Co. (NASDAQ:PODD) shares gapped down prior to trading on Friday . The stock had previously closed at $288.29, but opened at $276.35. Insulet shares last traded at $282.42, with a volume of 298,425 shares traded.

Wall Street Analysts Forecast Growth

Several brokerages have recently commented on PODD. Stifel Nicolaus lifted their target price on shares of Insulet from $245.00 to $293.00 and gave the company a “hold” rating in a research note on Friday. JPMorgan Chase & Co. upped their target price on shares of Insulet from $280.00 to $330.00 and gave the company an “overweight” rating in a research report on Thursday, December 12th. Canaccord Genuity Group boosted their price objective on Insulet from $304.00 to $324.00 and gave the company a “buy” rating in a report on Friday. Raymond James reaffirmed an “outperform” rating and set a $328.00 price target (up previously from $294.00) on shares of Insulet in a research note on Friday. Finally, Sanford C. Bernstein assumed coverage on Insulet in a report on Wednesday, November 6th. They issued an “outperform” rating and a $300.00 target price for the company. Three investment analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $286.25.

Insulet Trading Down 2.5 %

The company has a current ratio of 3.68, a quick ratio of 2.80 and a debt-to-equity ratio of 1.21. The firm has a market cap of $19.72 billion, a PE ratio of 48.17, a price-to-earnings-growth ratio of 3.56 and a beta of 1.23. The company has a 50-day simple moving average of $272.71 and a 200 day simple moving average of $246.47.

Insulet (NASDAQ:PODD) last released its quarterly earnings data on Thursday, February 20th. The medical instruments supplier reported $1.15 earnings per share for the quarter, beating analysts’ consensus estimates of $1.00 by $0.15. Insulet had a net margin of 21.22% and a return on equity of 27.98%. The company had revenue of $597.50 million during the quarter, compared to analysts’ expectations of $582.02 million. As a group, sell-side analysts forecast that Insulet Co. will post 3.22 earnings per share for the current fiscal year.

Insider Buying and Selling at Insulet

In related news, EVP Eric Benjamin sold 12,394 shares of the business’s stock in a transaction dated Tuesday, January 21st. The shares were sold at an average price of $280.00, for a total value of $3,470,320.00. Following the sale, the executive vice president now directly owns 11,383 shares in the company, valued at approximately $3,187,240. The trade was a 52.13 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, CAO Lauren Budden sold 915 shares of Insulet stock in a transaction that occurred on Tuesday, December 10th. The shares were sold at an average price of $275.62, for a total transaction of $252,192.30. Following the completion of the sale, the chief accounting officer now owns 5,733 shares of the company’s stock, valued at $1,580,129.46. This trade represents a 13.76 % decrease in their position. The disclosure for this sale can be found here. 0.47% of the stock is owned by corporate insiders.

Institutional Trading of Insulet

A number of large investors have recently modified their holdings of the stock. Blue Trust Inc. increased its position in shares of Insulet by 84.1% in the 3rd quarter. Blue Trust Inc. now owns 127 shares of the medical instruments supplier’s stock valued at $30,000 after purchasing an additional 58 shares during the last quarter. Venturi Wealth Management LLC boosted its stake in Insulet by 633.3% in the third quarter. Venturi Wealth Management LLC now owns 154 shares of the medical instruments supplier’s stock valued at $36,000 after acquiring an additional 133 shares in the last quarter. SBI Securities Co. Ltd. purchased a new position in shares of Insulet during the fourth quarter worth about $36,000. Itau Unibanco Holding S.A. acquired a new stake in shares of Insulet during the fourth quarter worth about $42,000. Finally, SRS Capital Advisors Inc. lifted its holdings in shares of Insulet by 43.1% in the 4th quarter. SRS Capital Advisors Inc. now owns 186 shares of the medical instruments supplier’s stock valued at $49,000 after purchasing an additional 56 shares during the last quarter.

Insulet Company Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.